Pathology of lung cancer

Tumors of the Chest: Biology, Diagnosis and Management

Volumn , Issue , 2006, Pages 93-105

  Wistuba, Ignacio I ^a   Gazdar, Adi F ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84883342363     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/3-540-31040-1_8     Document Type: Chapter

References (87)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. Ca Cancer J Clin 2005;55:10.
2. Minna JD, Gazdar A. Focus on lung cancer. Cancer Cell 2002;1:49.
3. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. Tumours of the lung. In: Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (eds.) Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. IARC Press, Lyon, 2004; p 9.
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57.
5. Fong KM, Sekido Y, Gazdar AF, Minna JD. Lung cancer. Molecular biology of lung cancer: clinical implications. Thorax 2003;58:892.
6. Herbst RS, Sandler AB. Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer 2004;6(Suppl 1):S7.
7. Herbst RS, Onn A, Sandler A. Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 2005;23:3243.
8. Wistuba, II, Mao L, Gazdar AF. Smoking molecular damage in bronchial epithelium. Oncogene 2002;21:7298.
9. Westra WH. Early glandular neoplasia of the lung. Respir Med 2000;1:163.
10. Parkin MD, Whelan SL, Ferlay J, et al. Cancer incidence in five continents. IARC Press, Lyon, 2002.
11. Travis WD, Lubin J, Ries L, Devesa S. United States lung carcinoma incidence trends: declining for most histologic types among males, increasing among females. Cancer 1996;77:2464.
12. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710.
13. Argiris A, Murren JR. Staging and clinical prognostic factors for small-cell lung cancer. Cancer J 2001;7:437.
14. Colby TV, Wistuba, II, Gazdar A. Precursors to pulmonary neoplasia. Adv Anat Pathol 1998;5:205.
15. Kerr KM. Pulmonary preinvasive neoplasia. J Clin Pathol 2001;54:210.
16. Wistuba II, Behrens C, Milchgrub S, et al. Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene 1999;18:643.
17. Wistuba, II, Behrens C, Virmani AK, et al. Allelic losses at chromosome 8p21-23 are early and frequent events in the pathogenesis of lung cancer. Cancer Res 1999;59:1973.
18. Wistuba, II, Behrens C, Virmani AK, et al. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res 2000;60:1949.
19. Belinsky SA, Nikula KJ, Palmisano WA, et al. Aberrant methylation of pl6 (INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl AcadSciUS A 1998;95:11891.
20. Wistuba II, Lam S, Behrens C, et al. Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst 1997;89:1366.
21. Mao L, Lee JS, Kurie JM, et al. Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst 1997;89:857.
22. Park IW, Wistuba, II, Maitra A, et al. Multiple clonal abnormalities in the bronchial epithelium of patients with lung cancer. J Natl Cancer Inst 1999;91:1863.
23. Kitamura H, Kameda Y, Ito T, Hayashi H. Atypical adenomatous hyperplasia of the lung. Implications for the pathogenesis of peripheral lung adenocarcinoma [see comments]. Am J Clin Pathol 1999;111:610.
24. Osanai M, Igarashi T, Yoshida Y. Unique cellular features in atypical adenomatous hyperplasia of the lung: ultrastructural evidence of its cytodifferentiation. Ultrastruct Pathol 2001;25:367.
25. Weng SY, Tsuchiya E, Kasuga T, Sugano H. Incidence of atypical bronchioloalveolar cell hyperplasia of the lung: relation to histological subtypes of lung cancer. Virchows Arch A Pathol Anat Histopathol 1992;420:463.
26. Nakanishi K. Alveolar epithelial hyperplasia and adenocarcinoma of the lung. Arch Pathol Lab Med 1990;114:363.
27. Chapman AD, Kerr KM. The association between atypical adenomatous hyperplasia and primary lung cancer. Br J Cancer 2000;83:632
28. Koga T, Hashimoto S, Sugio K, et al. Lung adenocarcinoma with bronchioloalveolar carcinoma component is frequently associated with foci of high-grade atypical adenomatous hyperplasia. Am J Clin Pathol 2002;117:106.
29. Yokose T, Doi M, Tanno K, et al. Atypical adenomatous hyperplasia of the lung in autopsy cases. Lung Cancer 2001;33:155.
30. Westra WH, Baas IO, Hruban RH, et al. K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Res 1996;56:2224.
31. Tominaga M, Sueoka N, Irie K, et al. Detection and discrimination of preneoplastic and early stages of lung adenocarcinoma using hmRNP Bl, combined with the cell cycle-related markers pl6, cyclin Dl, and Ki-67. Lung Cancer 2003;40:45.
32. Nakanishi K, Kawai T, Kumaki F, et al. Survivin expression in atypical adenomatous hyperplasia of the lung. Am J Clin Pathol 2003;120:712.
33. Yatabe, Y, Kosaka, T, Takahashi, T. & Mitsudomi, T EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol 2005;29:633.
34. Aguayo SM, Miller YE, Waldron JA, et al. Brief report: idiopathic diffuse hyperplasia of pulmonary neuroendocrine cells and airways disease [see comments]. N Engl J Med 1992;327:1285.
35. Armas OA, White DA, Erlanson RA, Rosai J. Diffuse idiopathic pulmonary neuroendocrine cell proliferation presenting as interstitial lung disease. Am J Surg Pathol 1995;19:963.
36. Wistuba, II, Berry J, Behrens C, et al. Molecular changes in the bronchial epithelium of patients with small cell lung cancer. Clin Cancer Res 2000;6:2604.
37. Brambilla E, Travis WD, Colby TV, et al. The new World Health Organization classification of lung tumours. Eur Respir J 2001;18:1059.
38. Travis WD, Garg K, Franklin WA, et al Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. J Clin Oncol 2005;23:3279.
39. Shimosato Y, Suzuki A, Hashimoto T, et al. Prognostic implications of fibrotic focus (scar) in small peripheral lung cancers. Am J Surg Pathol 1980;4:365.
40. Colby TV, Noguchi M, Henschke C, et al. Tumours of the lung. Adenocarcinoma. In: Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (eds.) Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. IARC Press, Lyon, 2004; p 35.
41. Noguchi M, Shimosato Y The development and progression of adenocarcinoma of the lung. Cancer Treat Res 1995;72:131.
42. Sabloff BS, Truong MT, Wistuba, II, Erasmus JJ. Bronchioalveolar cell carcinoma: radiologic appearance and dilemmas in the assessment of response. Clin Lung Cancer 2004;6:108.
43. Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 1995;75:2844.
44. Clayton E The spectrum and significance of bronchioloalveolar carcinomas. Pathol Annu 1988;2:361.
45. Colby TV, Koss MN, Travis WD. Tumors of the lower respiratory tract, 3rd. series, Fascicle 13. Washington, DC: Armed Forces Institute of Pathology, 1995; p 1.
46. Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002;62:6997.
47. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949.
48. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339.
49. Shigematsu H, Takahashi T, Nomura M, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 2005;65:1642.
50. Slebos RJ, Rodenhuis S. The ras gene family in human non-small-cell lung cancer. Monogr Natl Cancer Inst 1992;13:23.
51. Huang SF, Liu HP, Li LH, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004;10:8195.
52. Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64:8919.
53. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306.
54. Tokumo M, Toyooka S, Kiura K, et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 2005;11:1167.
55. Toyooka S, Tsuda T, Gazdar AE The TP53 gene, tobacco exposure, and lung cancer. Hum Mutat 2003;21:229.
56. Toyooka S, Maruyama R, Toyooka KO, et al. Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int I Cancer 2003;103:153.
57. Toyooka S, Suzuki M, Maruyama R, et al. The relationship between aberrant methylation and survival in non-smallcell lung cancers. Br J Cancer 2004;91:771.
58. Wistuba, II, Behrens C, Virmani AK, et al High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints Cancer Res 2000;60:1949.
59. Hammar SP, Brambilla C, Pugatch B, et al. Tumours of the Lung. Squamous cell carcinoma. In: Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (eds.) Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. IARC Press, Lyon, 2004; p 26
60. Jang KM, Lee KS, Shim YM, et al. The rates and CT patterns of locoregional recurrence after resection surgery of lung cancer: correlation with histopathology and tumor staging. J Thorac Imaging 2003;18:225.
61. Hirsch FR, Varella-Garcia M, Bunn PA, Jr., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003;21:3798.
62. Brambilla C, Travis WD. Tumours of the lung. Adenosquamous carcinoma. In: Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (eds.) Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. IARC Press, Lyon, 2004; p 51.
63. Brambilla C, Pugatch B, Geisinger K, et al. Tumours of the lung. Large cell carcinoma. In: Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (eds.) Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. IARC Press, Lyon, 2004; p 45.
64. Takei H, Asamura H, Maeshima A, et al. Large cell neuroendocrine carcinoma of the lung: clinicopathologic study of eighty-seven cases. J Thorac Cardiovasc Surg 2002;124:285.
65. Pittaluga S, Wong MP, Chung LP, Loke SL. Clonal Epstein-Barr virus in lymphoepithelioma-like carcinoma of the lung. Am J Surg Pathol 1993;17:678.
66. Kobayashi M, Ito M, Sano K, et al. Pulmonary lymphoepithelioma-like carcinoma: predominant infiltration of tumor-associated cytotoxic T lymphocytes might represent the enhanced tumor immunity. Intern Med 2004;43:32.
67. Onuki N, Wistuba, II, Travis WD, et al. Genetic changes in the spectrum of neuroendocrine lung tumors. Cancer 199;85:600.
68. Przygodzki RM, Finkelstein SD, Langer JC, et al. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome. Am J Pathol 1996;148:1531.
69. Corrin B, Chang YL, Rossi G, et al. Tumors of the lung. Sarcomatoid carcinoma. In: Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (eds.) Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. IARC Press, Lyon, 2004; p 53.
70. Rossi G, Cavazza A, Sturm N, et al. Pulmonary carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements: clinicopathologic and immunohistochemical study of 75 cases. Am J Surg Pathol 2003;27:311.
71. Wick MR, Ritter JH, Humphrey PA. Sarcomatoid carcinomas of the lung: clinicopathologic review. Am J Clin Pathol 1997;108:40.
72. Ro JY, Chen JL, Lee JS, et al. Sarcomatoid carcinoma of the lung. Immunohistochemical and ultrastructural studies of 14 cases. Cancer 1992;69:376.
73. Nishida K, Kobayashi Y, Ishikawa Y, et al. Sarcomatoid adenocarcinoma of the lung: clinicopathological, immunohistochemical and molecular analyses. Anticancer Res 2002;22:3477.
74. Travis WD, Nicholson S, Hirsch F, et al. Tumours of the lung. Small cell carcinoma. In: Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (eds.) Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. IARC Press, Lyon, 2004; p 31.
75. Nicholson SA, Beasley MB, Brambilla E, et al. Small cell lung carcinoma (SCLC): clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol 2002;26:1184.
76. Guinee DG, Jr., Fishback NF, Koss MN, et al. The spectrum of immunohistochemical staining of small-cell lung carcinoma in specimens from transbronchial and openlung biopsies. Am J Clin Pathol 1994;102:406.
77. Abrams J, Doyle LA, Aisner J. Staging, prognostic factors, and special considerations in small cell lung cancer. Semin Oncol 1988;15:261.
78. Wistuba, II, Gazdar AE Molecular pathology of lung cancer. Verh Dtsch Ges Pathol 2000;84:96.
79. Wistuba, II, Gazdar AF, Minna JD. Molecular genetics of small cell lung carcinoma. Semin Oncol 2001;28:3.
80. Girard L, Zochbauer-Muller S, Virmani AK, et al. Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res 2000;60:4894.
81. Toyooka S, Toyooka KO, Maruyama R, et al. DNA mediation profiles of lung tumors. Mol Cancer Ther 2001;1:61.
82. Flieder DB. Neuroendocrine tumors of the lung: recent developments in histopathology. Curr Opin Pulm Med 2002;8:275.
83. Beasley MB, Thunissen FB, Hasleton PS, et al. Tumours of the lung. Carcinoid tumor. In: Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (eds.) Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. IARC Press, Lyon, 2004; p 59.
84. Travis WD, Rush W, Flieder DB, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 1998;22:934.
85. Beasley MB, Thunnissen FB, Brambilla E, et al. Pulmonary atypical carcinoid: predictors of survival in 106 cases. Hum Pathol 2000;31:1255.
86. Debelenko LV, Brambilla E, Agarwal SK, et al. Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. Hum Mol Genet 1997;6:2285.
87. Kobayashi Y, Tokuchi Y, Hashimoto T, et al. Molecular markers for reinforcement of histological subclassification of neuroendocrine lung tumors. Cancer Sci 2004;95:334.